Management of Diastolic Dysfunction in This Patient
Continue the current regimen of lisinopril 20 mg and hydrochlorothiazide 12.5 mg daily, and add a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol) to optimize blood pressure control and improve diastolic function, with a target blood pressure of <130/80 mmHg. 1
Current Medication Assessment
Your patient is already on guideline-directed therapy for hypertension with diastolic dysfunction. The combination of an ACE inhibitor (lisinopril) and thiazide diuretic (hydrochlorothiazide) forms the foundation of appropriate treatment 1. This regimen addresses both blood pressure control and the underlying pathophysiology of diastolic dysfunction.
Blood Pressure Target
- Target BP: <130/80 mmHg 1
- Critical caveat for this 73-year-old patient: Exercise caution if diastolic blood pressure falls below 60 mmHg, as this can worsen myocardial ischemia in elderly patients with wide pulse pressures 1
- Monitor for symptoms of hypoperfusion, especially if systolic pressure lowering causes very low diastolic values
Adding Beta-Blocker Therapy
The evidence-based next step is adding a beta-blocker 1:
- Preferred agents: Carvedilol, metoprolol succinate, or bisoprolol (Class I; Level of Evidence A) 1
- These specific beta-blockers have proven outcomes in heart failure and are effective for blood pressure control
- Beta-blockers improve diastolic function by:
- Reducing heart rate, allowing more time for ventricular filling
- Decreasing myocardial oxygen demand
- Improving left ventricular relaxation
Lifestyle Modifications
Implement these non-pharmacological interventions (Class I; Level of Evidence C) 1:
- Sodium restriction: Essential for reducing volume overload
- Closely monitored exercise program: Improves diastolic function and functional capacity
- Weight management: Particularly important as obesity worsens diastolic dysfunction
Medications to AVOID
Do not use the following in this patient 1:
- Nondihydropyridine calcium channel blockers (diltiazem, verapamil): Negative inotropic effects worsen heart failure symptoms (Class III; Level of Evidence B)
- Alpha-blockers (doxazosin): Associated with 2-fold increased risk of heart failure development
- Clonidine or moxonidine: Associated with increased mortality in heart failure patients
If Blood Pressure Remains Uncontrolled
Sequential add-on therapy options 1:
- First addition: Beta-blocker (as discussed above)
- If still uncontrolled: Consider adding a long-acting dihydropyridine calcium channel blocker (amlodipine or felodipine) - these are safe in diastolic dysfunction 1
- Alternative: Switch to or add an ARB if ACE inhibitor is not tolerated 1
Monitoring Strategy
Assess the following at regular intervals:
- Blood pressure (both sitting and standing, given age >60 years) 2
- Symptoms of heart failure (dyspnea, edema, exercise tolerance)
- Renal function and electrolytes (especially potassium with ACE inhibitor + diuretic combination)
- Signs of excessive blood pressure lowering (dizziness, fatigue, syncope)
Evidence Limitations
While ACE inhibitors are guideline-recommended for diastolic dysfunction, one small study 3 showed lisinopril did not significantly improve diastolic parameters in isolated diastolic dysfunction. However, the overwhelming guideline consensus supports ACE inhibitor use for blood pressure control and cardiovascular risk reduction in this population 1. The benefits extend beyond direct effects on diastolic function to include prevention of disease progression and reduction in cardiovascular events.
Special Consideration for Aldosterone Antagonists
Consider adding spironolactone or eplerenone if heart failure symptoms worsen or if LVEF falls below 40% (Class IIa; Level of Evidence B) 1. These agents provide additional benefit in severe heart failure but require careful monitoring of potassium levels, especially when combined with ACE inhibitors.